Baxalta Announces U.S. Availability of ADYNOVATE, New Treatment for Adult Patients With Hemophilia A With a Simple, Twice-Weekly Dosing Schedule
November 30, 2015 at 06:45 AM EST
Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with ...